With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second. Demand for Eli Lilly's Mounjaro and Zepbound remains robust, and sell-side analysts tracking script data shows strong growth for both of these drugs.
Eli Lilly to trial use of weight loss drugs to combat unemployment in U.K.
U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K.
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss Drugs
In response to a lawsuit, the FDA said it would reconsider its previous decision to remove tirzepatide, the active compound in the weight loss and diabetes drugs Mounjaro and Zepbound, from its shortage list.
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of notable wins have me thinking this lead will widen. Earli
Could weight-loss drugs boost the economy?
Streeting announced a collaboration with the world's largest pharmaceutical company, Lilly, which will include a five-year trial investigating whether the use of the weight-loss d
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
Warning: This Skyrocketing Stock Has a Hidden Risk
All of this sounds fantastic and could make Lilly an excellent buy, but before you take action, consider this warning: This ...
Hims & Hers Stock Jumps as FDA Reconsiders Restrictions on Copycat Weight-Loss Drugs
Hims & Hers Health shares rose Monday after the Food and Drug Administration said compounding pharmacies could continue to ...
Why Eli Lilly Stock Is Soaring—And How It Plans To Stay On Top
In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.
Hosted on MSN2d
Lilly Loses Around $14B This Week: How to Play LLY Stock
The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.
Trade group sues FDA over ending Mounjaro/Zepbound shortage
A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...
Hims & Hers Health Stock Is Rising Monday: What's Going On?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday. The company is set to join to the S&P SmallCap 600 this ...
Medical Xpress4d
Mounjaro is more effective for weight loss than Ozempic—how does it work? And why does it cost so much?
,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is sold under the brand name Mounjaro and affects feelings of hunger and ...
Eli Lilly (LLY): Revenue Boost from Zepbound and Mounjaro Amid Strong Market Projections
We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Eli ...